SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 67.13 |
| Enterprise Value ($M) | 89.59 |
| Book Value ($M) | -19.68 |
| Book Value / Share | -0.43 |
| Price / Book | -3.41 |
| NCAV ($M) | -32.14 |
| NCAV / Share | -0.70 |
| Price / NCAV | -2.09 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.08 |
| Return on Assets (ROA) | -0.04 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.97 |
| Current Ratio | 1.08 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 57.25 |
| Assets | 69.71 |
| Liabilities | 89.39 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Nantahala Capital Management, LLC | |||
| 13G/A | Hirschman Orin | 8.10 | -10.36 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 4,150 | 27,470 | 15.11 | |
| 20,438 | 81,608 | 25.04 | |
| 16,936 | 73,028 | 23.19 | |
| 7,121 | 127,052 | 5.60 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| TENX – Tenax Therapeutics, Inc. | TGTX – TG Therapeutics, Inc. |
| THAR – Tharimmune, Inc. | TIL – Instil Bio, Inc. |
| TLSA – Tiziana Life Sciences Ltd |
Financial data and stock pages provided by
Fintel.io